TMCnet News
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Friday, May 9th CABN, MGRN, ZIOP, AYSI, CLXN, VOYT(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:09052008 Our Stocks to Watch today include Carbon Sciences Inc. (OTCBB: CABN), Monogram Energy Inc. (OTC: MGRN), ZIOPHARM Oncology Inc. (NASD: ZIOP), Alloy Steel Incorporated (OTCBB: AYSI), CLX Medical Inc. (OTC BB: CLXN), Voyant International Corp. (OTCBB: VOYT) Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts. CARBON SCIENCES INCORPORATED (OTCBB: CABN) Detailed Quote: http://www.otcpicks.com/quotes/CABN.php Company Profile: http://www.otcpicks.com/carbon-sciences/carbon-sciences-2.htm Carbon Sciences, Inc. focuses on developing GreenCarbon technology to convert carbon dioxide into a form that would not contribute to global warming. Its GreenCarbon technology is targeted at coal-fired electrical power plants and fuel production plants. The company was founded in 2006 as Zingerang, Inc. and changed its name to Carbon Sciences, Inc. in April 2007. Carbon Sciences, Inc. is based in Santa Barbara, California. CABN News: May 8 - RedChip Visibility Issues Fourth Quarter 2007 Research Update On Carbon Sciences, Inc. RedChip Visibility, a division of RedChip Companies, Inc. announced it has issued a fourth quarter 2007 research update on Carbon Sciences, Inc. (OTCBB: CABN), a company engaged in developing its GreenCarbon(tm) Technology which converts harmful carbon dioxide into useful carbon products. Neha Bhargava, MBA, RedChip Research Analyst, reported: "CABN continues to focus on developing and commercializing its GreenCarbon(tm) Technology. We consider the completion of CABN's Mobile Prototype as an initial positive mark toward the development of this technology. "CABN expects to develop its products and to focus its efforts on establishing markets in power plants and industrial factories by 2010. We believe CABN's carbon transformation is a better option compared with traditional carbon sequestration technologies," Bhargava continued. "As the world moves toward trimming the impact of global warming, the U.S. Department of Energy has set an objective to capture 90% of CO2 from the environment with 99% storage permanence at less than a 10% increase in energy costs, which itself would be a Herculean task. With the value of GreenCarbon Technology and the DOE's objectives, CABN has massive upside potential," she concluded. "We are assigning a 'Speculative Buy' rating to CABN stock with a 12-month target price of $0.32." To receive a complimentary copy of the RedChip Visibility Fourth Quarter 2007 Research Report for CABN, visit www.redchip.com/visibility/about.asp?page=vreport&reportid=105&from=0508 2008pr. MONOGRAM ENERGY INCORPORATED (OTC: MGRN) Detailed Quote: http://www.otcpicks.com/quotes/MGRN.php Company Profile: http://www.otcpicks.com/monogram-energy/monogram-energy.htm Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production. MGRN News: May 8 - Monogram Energy, Inc. Interview With Jordan Kimmel Monogram Energy, Inc. (OTC: MGRN), an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties, announced that CEO Billy King will be interviewed by Jordan Kimmel on his highly successful radio show, "Profitable Investing." The live interview will take place on Thursday May 08, 2008 at 11:45 AM EST and will be aired at www.modavox.com/VoiceAmericaBusiness. Mr. Kimmel is a regular contributor to numerous investing related periodicals, and his stock selection process has been featured in Forbes Magazine. Mr. Kimmel also makes frequent guest appearances on ABC News, CNBC and FOX Business, and hosts his own radio show on Voice America. "It's a great pleasure to speak with Mr. Kimmel on his radio program," stated Billy King, Chief Executive Officer of Monogram Energy, Inc. "This provides us with some invaluable exposure as we move forward." Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders. ZIOPHARM ONCOLOGY INCORPORATED (NASD: ZIOP) "Up 3.45% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/ZIOP.php ZIOPHARM Oncology, Inc., a biopharmaceutical company, develops and commercializes a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidates that are related to cancer therapeutics, which are already on the market or in development. The company's product candidates include darinaparsin (ZIO-101), palifosfamide (ZIO-201), and indibulin (ZIO-301). The ZIO-101, an organic arsenic compound, is in Phase II trial in patients with liver cancer, leukemia/lymphoma, and myeloma, as well as in Phase I trial for oral administration. The ZIO-201, a proprietary active metabolite of the pro-drug ifosfamide, is in Phase II trail in patients with advanced sarcoma, as well as Phase I/II trail in patients with sarcoma combination. The ZIO-301, an anti-cancer agent that targets mitosis like the taxanes, is in a Phase I trial. The company was founded in 2003 and is headquartered in New York, New York. ZIOP News: May 9 - ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma ZIOPHARM Oncology, Inc. (NASD: ZIOP) announced that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to palifosfamide in the treatment of Soft Tissue Sarcoma (STS). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States. The Orphan Drug designation provides eligibility for a seven-year period of market exclusivity in the United States after product approval, an accelerated review process, grant funding, tax benefits and an exemption from user fees. Soft tissue sarcomas represent a rare and diverse group of tumors that are not well understood. STS tumors can occur anywhere within the body including muscle, fat, nerves, vascular tissue, and other connective tissues. STS tumors account for about 1% of all cancers in adults and 10% in children. According to Cancer Statistics and the National Cancer Institute, there are an estimated 12,000 new cases of sarcomas diagnosed in the United States (US) each year, including approximately 9,000 cases of soft tissue sarcomas (STS) and 3,000 cases of bone sarcomas. Deaths attributable to STS are estimated at 3,500 per year, while 1,200 per year are due to bone sarcomas. Although the annual new incidence of sarcoma is relatively low, the prevalence of patients with sarcomas is quite high, with a 5-year survival rate of STS of 50% to 60%. "There is significant unmet need for additional soft tissue sarcoma treatment beyond locally effective surgery," said Jonathan Lewis, MD, PhD, and Chief Executive Officer of ZIOPHARM. "Palifosfamide has demonstrated activity against sarcomas in heavily pre-treated patients as well as evidencing fewer side effects than similar treatments used in this setting. We are pleased to have received Orphan Drug designation and look forward to continuing to work closely with the FDA in advancing palifosfamide toward commercialization." ABOUT PALIFOSFAMIDE Palifosfamide (IPM), the active moiety of ifosfamide (IFOS), is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking, resulting in cell death. Palifosfamide is equal to or more active than IFOS in diverse cancer models. Unlike IFOS, which is a pro-drug, palifosfamide is directly active against cancer cells. Also, unlike IFOS, palifosfamide is not metabolized to acrolein or chloroacetaldehyde which cause bladder or central nervous system toxicities. Intravenously (IV) administered palifosfamide is currently completing phase II testing in both advanced soft tissue and bone sarcomas, while a recently initiated phase I combination study with the FDA approved front-line therapy Adriamycin (doxorubicin) is ongoing. The final results from these studies will form the basis for an expected phase II randomized trial in the front- or second-line setting to initiate late in the third quarter of this year. Following further preclinical study, an oral form of palifosfamide is expected to enter phase I study in solid tumors early in 2009. ALLOY STEEL INTERNATIONAL INCORPORATED (OTCBB: AYSI) "Up 48.91% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/AYSI.php Alloy Steel International, Inc., together with its subsidiary, Alloy Steel Australia (Int.) Pty Ltd., engages in the manufacture and distribution of Arcoplate, a wear-resistant alloy overlay wear plate. It offers fused-alloy steel plates for installation and use in structures and machinery that suffer wear and hang-up problems. The company is also developing the 3-D Pipefitting Cladder process. Alloy Steel International's customer base primarily consists of companies involved in the mining and dredging industries in Australia, the United States, South America, India, Indonesia, Singapore, South Africa, Japan, China, Canada, and Malaysia. The company was founded in 2000 and is based in Malaga, Australia. AYSI News: May 9 - Alloy Steel Incorporated Announces Increased Sales and Profits Alloy Steel Incorporated (OTCBB: AYSI) had sales of $4,206,235 for the three months ended March 31, 2008, compared to $1,753,814 for the three months ended March 31, 2007. These sales consist solely of the sale of our Arcoplate product. Substantially all of our sales during the periods were denominated in Australian dollars. Sales were converted into U.S. dollars at the conversion rate of $0.89768 for the three months ended March 31, 2008 and $0.77805 for the three months ended March 31, 2007 representing the average foreign exchange rate for the respective year to date periods. Alloy Steel had sales of $7,386,574 and $3,412,121 for the six months ended March 31, 2008 and the six months ended March 31, 2007 respectively. These sales consist solely of our Arcoplate products. The sales increase is attributable to increased orders from new mining projects in Australia. Gross Profit and Cost of Sales Alloy Steel had cost of sales of $1,762,635 for the three months ended March 31, 2008, compared to $1,047,900 for the three months ended March 31, 2007. The gross profit amounted to $2,443,600 for the three months ended March 31, 2008, compared to $705,914 for the three months ended March 31, 2007. Alloy Steel had a cost of sales of $3,563,501 and $1,786,463 for the six months ended March 31, 2008 and the six months ended March 31, 2007 respectively. Alloy Steel's gross profit was $3,823,073 or 51.8% of sales, and $1,625,658 or 47.6% of sales, for the respective six month periods. The increase in gross profit margin has been achieved through negotiation of better raw materials prices for some supplies during the period, as well as increased production through the mill without the need to increase direct labor costs. Operating Expenses Alloy Steel had no material operating expenses other than selling, general and administrative expenses for the three and six months ended March 31, 2008 and 2007. Alloy Steel had selling, general and administrative expenses of $785,594 for the three months ended March 31, 2008, compared to $564,304 for the three months ended March 31, 2007. Alloy Steel had operating expenses of $1,552,175 and $1,091,722 for the six months ended March 31, 2008 and six months ended March 31, 2007 respectively. Factors contributing to the increased expenditure for both the three month and six month periods ended March 31, 2008, increased travel expenditure to assist marketing and increased labor costs for sales and administrative employees. Income (Loss) Before Taxes Alloy Steel's income before income tax expense was $1,650,121 for the three months ended March 31, 2008, compared to $148,937 for the three months ended March 31, 2007. Alloy Steel had a net income before income taxes of $2,285,980 and $534,801 for the six months ended March 31, 2008 and six months ended March 31, 2007 respectively. Net Income (Loss) Alloy Steel had a net income of $1,154,206 or $0.068 per share, for the three months ended March 31, 2008, compared to a net loss of ($27,561), or ($0.002) per share, for the three months ended March 31, 2007. An adjustment to recognize the use of prior year tax losses of Alloy Steel's Australian subsidiary was made during the three month period ended March 31, 2007 as it was determined at that time that it was likely for the subsidiary to recoup all prior year tax losses that had accumulated resulting in the reported net loss for that period. The tax losses of the subsidiary have been recouped and the subsidiary is recognizing its accruing tax liability in each quarter. Alloy Steel had a net income of $1,588,911, or $0.094 per share, and $358,303, or $0.021 per share, for the six months ended March 31, 2008 and six months ended March 31, 2007 respectively. It is noted that predominantly all operations of Alloy Steel are conducted by the Australian subsidiary, and therefore, the majority of the amounts reported are initially recorded in Australian dollars by the subsidiary. The difference in the value of the Australian dollar compared to the US dollar has been reducing, and therefore the exchange rate movement has had an increasing impact upon the value reported by the Company. Liquidity and Capital Resources For the three months ended March 31, 2008, net cash provided by operating activities was $982,297, consisting of net income of $1,588,911 adjusted for depreciation and impairment expenses of $133,230 to reconcile net income to net cash provided by operating activities and an increase in cash and cash equivalents attributable to changes in operating assets and liabilities of $739,844 which consisted primarily of a decrease in accounts receivable and other current assets of $810,910 which was offset by an increase in income tax payable of $171,792 and decreasing accounts payable and other current liabilities of $100,726. As of March 31, 2008, the Company had a working capital surplus of $2,455,947. CLX MEDICAL INCORPORATED (OTCBB: CLXN) "Up 20.00% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/CLXN.php CLX Medical, Inc. is focused on the launch and distribution of unique medical diagnostic testing products. The Company currently owns a majority interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets. More information regarding Zonda can be found on the Company's official website, www.zondaincusa.com. CLX and Zonda are working together to achieve FDA clearance for Zonda's rapid point of care test for chlamydia, so that it can be distributed in the United States. The chlamydia product has been sold in selected European markets for approximately three years. CLX is also seeking to identify additional innovative products as potential acquisitions and opportunities for distribution relationships. CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. CLXN News: May 7 - CLX Medical, Inc. Announces Increasing Interest and Sales of Zonda's Rapid Point of Care Test for Chlamydia European Health Agencies Focus on the Growing Chlamydia Epidemic CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, announced that the company's European distributors have reported an increased interest in diagnostic testing products for chlamydia, which has resulted in increased sales of Zonda Incorporated's rapid point of care test for chlamydia by those distributors. Distributors in the United Kingdom, Belgium, the Netherlands and Luxemburg have reported the increase over recent months and attribute it to a greater focus on screening for chlamydia by national health organizations in those countries. The National Chlamydia Screening Programme (NCSP) in the United Kingdom has put an increased focus on the chlamydia epidemic and encourages testing for all sexually active men and women under the age of 25. The program in England was established in 2003 with the objective of controlling chlamydia through the early detection and treatment of asymptomatic infection. As in the United States, chlamydia is now the most commonly reported sexually transmitted infection in the UK. "Given the growing chlamydia epidemic, it is no surprise that interest in chlamydia screening products, including Zonda's HandiLab-C test for Chlamydia, is increasing in Europe as well as in the United States," commented Vera Leonard, chief executive officer of Zonda and CLX. "Chlamydia is a serious health problem, and we are currently positioning the Zonda chlamydia testing product to serve as an effective and readily available screening rapid point of care device for health care professionals worldwide." CLX currently holds a majority interest in Zonda, which has developed rapid point of care tests for medical and non-medical markets. Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's chlamydia product has been distributed in Europe for approximately three years. CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets. As part of the preparation for clinical trials, a validation study has been commissioned in order to perfect the testing protocol. The company has also identified and is in negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market. The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures. "Even as we continue through the process of achieving FDA clearance in the United States, we will also work with our selected master distributor to increase the use of the HandiLab-C in the European market," added Ms. Leonard. VOYANT INTERNATIONAL CORPORATION (OTCBB: VOYT) "Up 18.00% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/VOYT.php Voyant International Corporation, a media and technology holding company, focuses on identifying and developing various media-based technologies, media assets, and strategic partnerships to deliver commercial and consumer solutions. The company, through its subsidiary, Rocketstream Holding Corporation, develops a protocol technology to deliver rich-media content over the Internet. Its combined suite of technologies comprises integrated components based on its proprietary packet protocol, data encryption technologies, and acceleration transports. RocketStream provides its technologies for the delivery of video, audio, and groupware chat, as well as bi-directional voice over IP facilities; and a solution for file transfer and media delivery over IP network. The company's other subsidiary, Centerpoint Broadband Technologies, operates as an optical networking and wireless communications company. It builds an optical networking platform and a broadband wireless platform around high speed communication technologies for military applications. Voyant International has a joint venture to develop the Sports Immortals Cyber Museum internet portal, an immersive and interactive online showcase that celebrates the memories and achievements of the athletes in sports history. The company was founded in 1994 as Zeros & Ones, Inc. and later changed its name to Voyant International Corp. in April, 2007. Voyant International is headquartered in Palo Alto, California. VOYT News: May 8 - Voyant Announces Annual Shareholder Meeting Shareholder Meeting to Be Held June 4, 2008 in Sunnyvale, Calif. Voyant International Corporation (OTCBB: VOYT), a diversified media and technology holding company, announced today that it will hold its annual shareholder meeting on June 4, 2008 in Sunnyvale, California. The meeting will begin at 9:00 AM at the Domain Hotel, which is located at 1085 East El Camino Real, Sunnyvale, Calif. The meeting is expected to last approximately two hours. The company notes that the record date for this meeting will be May 13, 2008. The company invites those shareholders and members of the general public who wish to attend this meeting to register by sending an e-mail to [email protected]. ABOUT OTCPICKS.COM OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at [email protected]. Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever. Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks is receiving nine thousand dollars directly from the company for CABN advertising and promotion services. OTCPicks.com has received fifty thousand free trading shares from a non-controlling third party (Microcap Management) for MGRN advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. Third Party Web Sites and Information: OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: [email protected] ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2008 M2 Communications Ltd. |